A Breakthrough in Triple-Negative Breast Cancer Treatment

Learn More About Sacituzumab Govitecan

The 36th Annual J.P. Morgan Healthcare Conference

On Thursday, January 11, 2018 at 11:30am PST, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company and its strategic priorities. Click the link below to register for the webcast.

An Advanced Antibody-Based Therapeutics Company

Immunomedics is committed to being a leading, innovative biopharmaceutical company, dedicated to improving patient’s health and quality of life with novel antibody–based therapeutics for the treatment of cancer, autoimmune and other serious diseases.

Our Drive to Improve Targeted Therapies of Diseases

We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.

Pipeline

We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.

Magnifying glass with people

Explore how we turn our research into reality.

Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.

Clinical Trials